Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer

Stephen L. DeAngelo; Liang Zhao; Sofia Dziechciarz; Myungsun Shin; Sumeet Solanki; Andrii Balia; Marwa O. El-Derany; Cristina Castillo; Yao Qin; Nupur K. Das; Hannah N. Bell; João A. Paulo; Yuezhong Zhang; Nicholas J. Rossiter; Elizabeth C. McCulla; Jianping He; Indrani Talukder; Wai‐Lung Ng; Zachary T. Schafer; Nouri Neamati; Joseph D. Mancias; Markos Koutmos; Yatrik M. Shah

doi:10.1158/0008-5472.29761157

Key Points

AlkBH8 knockdown significantly affects GPX1/2 protein levels in colorectal cancer cells.
Sodium selenite shows potential to rescue growth deficits under RSL3 and auranofin treatments.
Colony formation assays provide evidence of altered cell behavior due to AlkBH8 KD.
Findings suggest selenoproteome as a promising target for drug development in colorectal cancer.

Implication

Supplementary figure examines AlkBH8's effect on GPX1/2 levels and CRC growth, hinting at therapeutic avenues.

Abstract

Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

DeAngelo et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfc80 https://doi.org/10.1158/0008-5472.29761157

View Full Paper

Ask AI

Bookmark

Share

Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading